allergic rhinitis
Conditions
Interventions
experiment group:dust mite mixture under the tongue
Sponsors
The Eye and ENT Hospital of Fudan University
Eligibility
Sex/Gender
All
Age
4 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) Aged 18 to 60 years old (including 18 and 60 years old) volunteers, men and women; (2) the clinical diagnosis of patients with mild to moderate allergic asthma, merger or not perennial allergic rhinitis; (3) two days scoring at least 2 points of the cleaning period of asthma symptom scores in 3 days ; (4) dust mites, household dust mites skin prick test results determine are all positive, according to the equivalent of histamine ++ or ++ above; (5) dust mites and house dust-mite-specific IgE acuity =0.7 kU/L; (6) Be able to understand and sign informed consent; (7) Good compliance;
Exclusion criteria
Exclusion criteria: (1) with a stomach, spleen, liver, kidney and other severe chronic medical history, medical history, or physical examination found that should not be involved; (2) often badly addicted to drugs, alcohol, smoke more than 20 (daily); (3) with a history of drug allergy; (4) none dust mites allergic patient, such as allergic to pollen in Spring and Autumn, German cockroach, cat, dog fur, whose original skin prick test reaction intensity is stronger than the dust mites allergens, and the results showed positive response more than ++; (5) treating by beta blockers; (6) Was treated by surgery within 4 weeks; (7) used systemic corticosteroids (oral and intravenous drug delivery, etc.) 4 weeks before enrollment; (8) except asthma or allergic rhinitis patients with confirmed by history or signs of any activity, acute or chronic Obstructive pulmonary disease; (9) three times fewer than expected value 60% of the PEF at the acute onset of the patients asthma; (10) with factors of affecting drug absorption, distribution, metabolism and excretion; (11) participated in other drug test within past three months; (12) pregnancy and lactation women or women have a pregnancy plan nearly 1 years in the future; (13) patients with poor compliance of research plan; (14) with a history of specific immune therapy; (15) those to be considered not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical effecacy and safety; | — |
Countries
China
Contacts
Public ContactDehui Wang
The Eye and ENT Hospital of Fudan University
Outcome results
None listed